Tempest Therapeutics, Inc.

Dozens of public biopharmaceutical companies have announced plans in 2025 to assess strategic alternatives after clinical trial setbacks or as cash stockpiles dwindled. Both ESSA Pharma and Elevation

The past year has seen an increase in investment in biopharma companies following a couple of lean years, but the sector is not fully out of the woods yet. However, most industry leaders see funding

Investors’ reaction to the success of Tempest Therapeutics, Inc. ’s liver cancer trial hit on 11 October was extraordinary – and a new analysis by Scrip shows just how extraordinary it was. The med

Addition of the PPAR⍺ antagonist TPST-1120 to standard of care in hepatocellular carcinoma (HCC) boosted survival in an ongoing Phase I/IIb study, Tempest Therapeutics, Inc. said on 11 October. The